Innovations Spur Medtech Investments
Bill Sideris |
December 05, 2017
In a new subsector report presented at the Northeast MedTech
Summit in Boston, which was organized by SVB, SVB analyzed the
investment and M&A activity of private, venture-backed medtech companies.
Investment is poised to surpass 2016 levels, driven in part by two recent
developments: monitoring devices that help expand care beyond traditional
healthcare settings and advancements in neuromodulation.
Here are some additional insights you’ll glean from the
- Device investing in 2017 is on track to surpass
2016, approaching its historical share of overall invested venture dollars
- Early-stage medtech investing in 2017 is set to
exceed 2016 in both the number of deals and the number of dollars invested
- Corporate venture funds continue to play a
central role in the landscape of medtech investors, with increasing
participation from private equity firms and family offices
- Strong investment in medtech technologies based
on artificial intelligence and robotics suggests that the sector is poised to
have a transformational impact on healthcare
- The M&A environment for medtech remains
robust, and the difference in exit multiples in favor of premarket approval and
de novo 510(k) regulatory pathways continues
Download the full report to learn more.
About the Author
Bill Sideris is a Senior Associate with SVB Securities, conducting M&A advisory engagements involving early stage, venture-backed companies in the Healthcare and Life Sciences sectors. Prior to joining SVB Securities, Bill Sideris developed medical devices for ophthalmic and cardiovascular indications in both Fortune 500 and start-up organizations.
Bill Sideris graduated with a Professional Doctorate degree in engineering from the Technical University of Delft and a Master of Science degree in biomedical engineering from the University of Houston.
Now Let's Get Started
See how Silicon Valley Bank makes next happen now for entrepreneurs like you.
Connect With Us